Fiche centre
TG Therapeutics Investigational Trial Site
Ternopil — Ukraine
Essais liés3clinical trials
VilleTernopillocalisation
PaysUkrainelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07503873
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ublituximab | SEP | Phase 2 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT07211633 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |